Microcap Ledger

Tickers · $NGNE

Neurogene Inc. $NGNE

By Microcap Ledger desk · CIK 0001404644

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Global Market
Sector
Pharmaceutical Preparations
Headquarters
New York, NY
Fiscal year end
December 31
Shares outstanding
20,011,382 [10-Q 2026-08-11]
as of 2026-08-07

Sources: [10-K 2026-03-24]

What the company doesAI summary of filing

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. The company's lead program, NGN-401, utilizes its proprietary EXACT transgene regulation technology to deliver a therapeutic MECP2 gene for the treatment of Rett syndrome and is currently in Phase 3 clinical development. Neurogene generates no revenue and has incurred net losses of $90.4 million and $75.1 million for the years ended December 31, 2025 and 2024, respectively, with accumulated losses of $352.6 million as of December 31, 2025. The company has raised approximately $552.1 million in net proceeds to date and operates a fully functional cGMP manufacturing facility in Houston, Texas. [10-K 2026-03-24]

Segments: NGN-401 (Rett syndrome) - Phase 3, EXACT platform technology, Early-stage discovery programs

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026—−$65.42M −$49.88M$112.48M[10-Q 2026-08-11]
FY ended Dec 2025$0.00−$90.35M −$77.17M$103.84M[10-K 2026-03-24]
FY ended Dec 2024$925.0K−$75.14M −$70.60M$136.59M[10-K 2026-03-24]
Quarterly cash burn
−$24.94M
Cash runway Estimate
~13.5 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-1314,854,725[10-Q 2024-11-18]
2025-03-1814,929,566[10-K 2025-03-24]
2025-05-0514,262,066[10-Q 2025-05-09]
2025-08-0614,271,916[10-Q 2025-08-11]
2025-11-1115,489,800[10-Q 2025-11-13]
2026-03-1815,574,293[10-K 2026-03-24]
2026-05-0815,801,901[10-Q 2026-05-12]
2026-08-0720,011,382[10-Q 2026-08-11]
Shelf registration
S-3 filed 2025-03-24; declared effective 2025-04-04 [S-3 2025-03-24]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-09-22Mcminn Rachelexercise756$25.32[4 2026-10-02]
2026-07-07Cvijic Christine Mikailsell4,200$36.13[4 2026-07-07]
2026-07-06Cvijic Christine Mikailsell600$36.02[4 2026-07-07]
2026-07-02Cvijic Christine Mikailsell2,531$34.58[4 2026-07-02]
2026-07-02Cvijic Christine Mikailsell1,530$35.23[4 2026-07-02]
2026-07-01Cvijic Christine Mikailsell739$34.06[4 2026-07-02]
2026-05-06Cvijic Christine Mikailsell4,800$30.07[4 2026-05-08]
2026-05-06Cvijic Christine Mikailsell4,800$32.44[4 2026-05-08]
2026-03-26Cvijic Christine Mikailsell2,558$21.62[4 2026-03-30]
2026-03-26Mcminn Rachelsell3,352$22.07[4 2026-03-30]
2026-03-26Jordan Juliesell828$21.89[4 2026-03-30]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-10-0713GBeneficial ownership report (5%+ holder)
2026-10-0613GBeneficial ownership report (5%+ holder)
2026-08-1413G/ABeneficial ownership report (5%+ holder)
2026-08-1413G/ABeneficial ownership report (5%+ holder)
2026-08-1413GBeneficial ownership report (5%+ holder)
2026-08-1110-QQuarterly report
2026-08-118-KResults of operations
2026-07-028-KMaterial agreement entered; Other events
2026-07-02424B5Prospectus or prospectus supplement
2026-06-30424B5Prospectus or prospectus supplement
2026-06-298-KRegulation FD disclosure; Other events
2026-06-088-KRegulation FD disclosure

Facts as of . Small caps move fast; check the latest filings.